{"url_path":"/sec/pvla/8-k/2026-06-30/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1583648/0001104659-26-079087-index.html","accession_number":"0001104659-26-079087","cik":"0001583648","ticker":"PVLA","issuer_name":"PALVELLA THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1583648/0001104659-26-079087-index.html","primary_entity_key":"0001583648","primary_entity_name":"PALVELLA THERAPEUTICS, INC."},"word_count":311,"has_tables":true,"body_markdown":"false\n0001583648\n\n0001583648\n\n2026-06-29\n2026-06-29\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n**CURRENT\nREPORT**\n\n \n\n**Pursuant\nto Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event reported): **June 29, 2026**\n\n \n\n \n\n**PALVELLA THERAPEUTICS, INC.**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\n \n\n**Nevada**\n**001-37471**\n**30-0784346**\n\n(State or other jurisdiction\n\nof incorporation)\n(Commission File Number)\n(IRS Employer\n\nIdentification No.)\n\n \n\n**353 W. Lancaster Ave, Suite 200**\n \n\n**Wayne, Pennsylvania**\n**19087**\n\n(Address of principal executive offices)\n(Zip Code)\n\n \n\nRegistrant’s telephone number, including\narea code: **(484) 253-1461**\n\n \n\n(Former\nname or former address, if changed since last report)\n\n \n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions:\n\n \n\n¨ \nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant\nto Section 12(b) of the Act:\n\n \n\n**Title of each class**\n \n**Trading\nSymbol(s)**\n \n**Name of each\nexchange on which registered**\n\nCommon stock, $0.001 par value per share\n \nPVLA\n \nThe Nasdaq Global Market\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities\nExchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ¨\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ¨"}